dexpramipexole
AssetAlso called Dexpramipexole Dihydrochloride
Reduces blood absolute eosinophil counts
- Stage
- Phase 2
- Modality
- Small molecule
- Target
- Not known
- 1
- Indication
- 2
- Trials
- 1
- Developer
Indications
1Chronic obstructive pulmonary disease
Phase 2, Active not recruiting, NCT06533553, clinicaltrials.gov, Oct 31, 2026
In the full profile
- Owner and partners1
- Trials2
- Evidence for its targets1
- Competitors12
- Aging relevance1
Every asset’s record: target, stage, trials and the evidence behind it.